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 INTRODUCTION
Neuroendocrine tumors of  the gastrointestinal  tract  are  not  a  rare 
entity.  Neuroendocrine  tumors  were  initially  called  APUDOMAs  and  were 
believed to be of neural crest origin. Later the endodermal origin was established. 
Due to the neurotransmitter like substance production the name neuroendocrine 
tumors have remained.
These tumors occur anywhere in the gut with a higher incidence in 
the large intestine.
Many attempts have been made to classify these tumors. The first 
classification  was  based  on  topography,  then  histological  pattern,  recently  on 
immunohistochemical  marker  expression.  Amongst  the  many  neuroendocrine 
markers Chromogranin A, Synaptophysin are the most useful. 
Most  cases  of  well  differentiated  neuroendocrine  tumors  the 
diagnosis  is  easily  made  from  the  histological  appearance.  But  in  less  well 
differentiated types  the  interpretation poses  a challenge.  A correct  diagnosis  is 
required  because  of  the  prognostic  implication  and  variation  in  treatment 
modalities.
 This  work  aims  at  confirming  histologically  diagnosed  cases  of 
neuroendocrine  tumors  and  also  detects  neuroendocrine  differentiation  in 
otherwise  exocrine  and  poorly  differentiated  tumors  with  the  help  of 
immunohistochemical markers Chromogranin A and Synaptophysin. 
The  association  between  neuroendocrine  marker  expression  and  their 
prognostic implication has also been studied.
AIMS AND OBJECTIVES
• To  detect  and  confirm  neuroendocrine  tumors  of  gastrointestinal  tract  by 
immunohistochemistry,  especially  in  cases  where  other  malignant  tumors 
cannot be excluded based on routine Hematoxylin and eosin stained sections 
alone
• To assess the extent of neuroendocrine differentiation in adenocarcinomas of 
gastrointestinal tract 
• To determine the prognostic significance of neuroendocrine marker expression 
in  the above categories
REVIEW OF LITERATURE
Neuroendocrine system is a dispersed system of cells with an endocrine and 
paracrine  function.  They are  embryologically  diverse  but  share  some common 
functional characteristics that define them physiologically and diagnostically when 
they form tumors. They are also clinically fascinating because of their hormonal 
effects and syndromic effects.
Gastrointestinal system has the largest population of neuroendocrine cells. 
[1]
Neuroendocrine  system – it  consists  of  a  variety  of  cells  present  in  the 
CNS, PNS and in many organs including classic endocrine organs
• Heidenhain  in  1980  described  chromaffin  cells  in  the  GIT  and 
suggested endocrine function
• Oberndofer in 1907 introduced the term carcinoid , an ileal tumor 
with a different behaviour from colon carcinoma
• Feyer in 1938 described clear cells in the GIT and suggested that 
they formed a part of the dispersed epithelial endocrine system and 
that some cells could have a paracrine effect [2].
• These cells  have  the  ability  to  take  up  amine precursors  such as 
DOPA AND 5-hydroxy tryptophan and subsequently decarboxylase 
them – these were termed APUD cells [3].
• There  are  14  endocrine  cell  types  in  the  gut  and  along with  the 
pancreas producing at least 33 hormones and biogenic amines [4].
Components of diffuse neuroendocrine system 
• GIT, bronchopulmonary and urothelial tract endocrine cells.
• Peptide and amine producing cells – C cells, islet cells of pancreas, 
pituitary and parathyroid cells.
• Chromaffin  cells  of  adrenal  medulla,  carotid  body  and  other 
paraganglia and Merkel cells of the skin
• Excludes hormone producing cells of the adrenal cortex, testis, ovary 
and thyroid follicular cells.
Why neuroendocrine?
• Pearse was the first to suggest that the diffuse endocrine system was 
of neural crest origin because of the similarity between APUD cells 
[amine  precursor  uptake  and  decarboxylation]  and  neurons. 
Similarities  being  production  of  bioactive  substances  that  serve 
transmitter functions, contain secretory granules and similar cellular 
antigens [5].
• Le Doufarin refuted the neural crest origin based on embryological 
data
• GIT and bronchopulmonary carcinoids are definitely of endodermal 
origin.
• Only  cells  of  proven  neural  crest  origin  are  –  cells  of  adrenal 
medulla, paraganglia and sympathetic ganglia.
• These  cells  produce  substances  similar  to  neurotransmitters/ 
neurohormones  such  as  cholinesterases,  peptides,  hormones  and 
substances for paracrine regulation – somatostatin.
• The  term  carcinoid  literally  means  carcinoma-like  was  coined  in 
1907  to  describe  the  histological  similarity  of  these  tumors  to 
carcinomas on one hand and their general indolent behavior on the 
other [6].
• 1963 William and Sandler classified carcinoid tumors on the basis of 
embryogenesis into foregut, midgut and hindgut carcinoids
Neuroendocrine  tumors  comprise  approximately  2%  of  all  malignant 
tumors of the gastrointestinal system. They have been classified into two types – 
the carcinoid and neuroendocrine carcinomas. The incidence of all non – carcinoid 
neuroendocrine tumors is approximately one half of that of all carcinoids [7]. Non-
carcinoid neuroendocrine tumors have been reported to occur in 0.4 – 1.5/100,000 
of the population [8].
Site of occurrence of neuroendocrine tumors:
Neuroendocrine tumors are most common in the large intestine (especially 
in the descending colon and recto sigmoid) [9] closely followed by the appendix 
and the small intestine.
Carcinoids in GIT are more prevalent in the appendix and small intestine 
followed by the rectum and it is least common in stomach [10].
Origin (or) tumor hypothesis:
Jejuno-ileal tumors arise from IECH [intraepithelial endocrine hyperplasia]. 
The progenitor cells are intraepithelial and these tumors arise from an area that has 
been diffusely primed for their development – field effect.
Appendicular carcinoids – arise from sub-epithelial complex not associated 
with IECH [11].
Gastric  carcinoids – ECL hyperplasia and tumor development associated 
with  hypergastrinemic  states  due  to  unregulated  hormone  (gastrin)  production. 
Increased  incidence  found  in  case  of  autoimmune  chronic  atrophic  gastritis, 
Zollinger Ellison syndrome and MEN-TYPE 1 syndrome.
Net morphology:
• Pattern – nests, cords, rosettes, islands, small glands, sinusoidal stroma.
• Cytology –  central  or  eccentric  nuclei,  stippled  chromatin  [salt  and  pepper 
nuclei]
Histochemistry  of neuroendocrine tumours
• Chromaffin  reaction  –  histological  staining  affinity  for  chromium salts  and 
silver salts.
• Argyrophilia – staining with silver salts in the presence of a reducing agent
• Argentaffinity - histological staining affinity for silver salts.
• Formalin induced fluorescence
• Neurosecretory granules.
 
Initial markers of neuroendocrine cells were argentaffin and argyrophilic 
reaction.  Carcinomas with numerous  argentaffin  or  argyrophilic  reactions  were 
termed atypical carcinoids or neuroendocrine carcinoma [12]. 
Based on these reactions,  gastric cancers with endocrine cells have been 
classified by Tahara E et al as:
1. Classical carcinoids
2. Endocrine  cell  carcinoma  showing  poorly  differentiated 
adenocarcinoma  
3. Endocrine cell cloning due to differentiation of carcinoma cell
4. Scirrhous argyrophilic cell carcinoma [13]. 
Markers of neuroendocrine differentiation
Hormonal markers: 
Calcitonin,  gastrin,  somatostatin,  vasointestinal  peptide,  serotonin, 
pancreastatin – almost 3 dozen products. Many of these substances when produced 
in excess produce specific clinical syndromes [14].
Non-hormonal markers:
1. Chromogranin - acidic proteins in secretory granules [TYPE A , B and 
Sg II]
2. Synaptophysin
3. Pro-Convertases
4. Bombesin , Lei 7 And Grp
5. neuron specific enolase
Chromogranin A considered as a realistic marker of neuroendocrine cells as 
it is a specific matrix component of endocrine granules.
A Blood level of chromogranin is also one of the best non-specific markers 
except in cases of insulinoma where chromogranin B can be used [14].
Synaptophysin is localized within a small capsule membranes related to the 
secretion granules, its specificity and sensitivity less than chromogranin. NSE has 
poor specificity and widely distributed in all tissues [15, 16]. 
Classification of Gastro-entero-pancreatic neurondocrine tumors 
WHO CLASSIFICATION - 2000
Neoplasm categories
℘ well differentiated neuroendocrine tumor
 benign
 uncertain behaviour
℘ well differentiated neuroendocrine carcinoma
℘ poorly differentiated neuroendocrine carcinoma
℘ mixed exocrine – endocrine carcinoma
℘ tumor like lesions [17,18]. 
Classification of Gastro-entero-pancreatic neurondocrine tumors 
WHO CLASSIFICATION - 2000
Classification of neuroendocrine neoplasms
(Based on neuroendocrine neoplasms of lung proposed by TRAVIS [19] and was 
subsequently used to classify neuroendocrine neoplasms of gastrointestinal tract 
[45])
• Typical carcinoids
• Atypical carcinoids
• Large cell neuroendocrine carcinoma
• Small cell carcinoma
Grading of immunohistochemical neuroendocrine marker distribution [19]
• 0 – none
• 1 – < 10% of tumor cells
• 2 - 10% to 50% of tumor cells
• 3 - > 50% of tumor cells
Staining intensity
• 1+   = mild
• 2+   = moderate
• 3+   = marked
Neuroendocrine tumors were more than 50% positive for neuroendocrine markers 
with a 2+ or 3+ staining intensity.
Typical carcinoids
Growth pattern – organoid, others solid, spindle cell, glandular, pallisading, 
oxyphilic, papillary and follicular
Cells – uniform size with moderate n: c ratio 
Nuclei – fine granular to stippled chromatin
Mitoses – rare
Necrosis – not seen
Vascular invasion – may be seen
Site:  Carcinoids  tumors  of  gastrointestinal  tract  are  most  common in  the 
appendix followed by small intestine, the rectum, and the stomach. Carcinoids are 
rare in the Ampulla of Vater [20] occurring in lower mean age than those with 
Adenocarcinoma  of  the  region.  Carcinoids  of  Ampulla  of  Vater  carry  a  good 
prognosis [21]
Atypical carcinoids
Growth  pattern  –  organoid,  others  solid,  spindle  cell,  pseudo  glandular, 
pallisading, oxyphilic.
Cells – uniform size with moderate n : c ratio
Nuclei – fine to slightly coarse nuclear chromatin and faint nucleoli. Nuclear 
pleomorphism present
Mitoses – rare 4 to < 10 mitoses per HPF
Necrosis – foci of necrosis
Vascular invasion and interstitial pattern of spread of pattern seen
Large cell neuroendocrine carcinoma [17]
Neuroendocrine carcinomas are  heterogeneous and potentially  aggressive when 
compared with classic carcinoids [22].
Neuroendocrine by appearance by light microscopy [organoid, pallisading or 
rosette like pattern]
Cytological features of large cells [most cells greater than nuclear diameter of 
3  resting  lymphocytes,  low  nuclear  cytoplasmic  ratio,  polygonal  shape,  fine 
granular  eosinophilic  cytoplasm  with  an  eosinophilic  hue  ,  coarse  nuclear 
chromatin, and frequent prominent  nucleoli]
Mitoses greater than 10/10 high power field.
Necrosis present consists of large infarct like areas.
Hematoxylin staining of DNA encrustation of vessel walls seen
Neuroendocrine features either by IHC or EM or both.
Mitotic figures were formed at a magnification of x400 counting 3 sets of 10 
high power fields for each tumor. Areas with highest number of mitoses were 
counted. 
Small cell carcinoma
Growth pattern – nesting, solid, pallisading and spindle pattern
Cells – small [less than nuclear diameter of three small resting lymphocytes], 
round to fusiform cells
Nucleus – high n: c ratio, hyperchromatic nuclei with fine granular chromatin 
and absent or inconspicuous nucleoli
Necrosis – present
Mitosis – high
Hematoxylin decoration of DNA encrustation of vascular walls seen.
Electron microscopy
Typical carcinoids – numerous granules, 90-450 nm variable round to oval
Atypical carcinoids – moderate numbers, diffuse distribution, 100-200 nm 
less variation
Large  cell  neuroendocrine  carcinoma  –  100-270  nm  focal  or  patchy 
distribution, minimal variation. 
PROGNOSIS
Tumor type
Typical carcinoids – indolent tumors, carry an excellent prognosis.
Atypical carcinoids – 70 % metastasis, 30% died; mean survival 27 months, mean 
survival – 25 months, 21 months [23]
Peripheral Small cell neuroendocrine carcinoma 
Low grade – mean survival 21 months, 
High grade – 19.1 months [23].
Large cell neuroendocrine carcinomas carry a bad prognosis [24].
Size of the tumor – > 2cm carries a bad prognosis [10]. However size alone is not 
a good independent predictor.
Adenocarcinomas with neuroendocrine differentiation
Incidence of neuroendocrine differentiation is common in carcinomas arising 
in organs that normally contain neuroendocrine cells such as the gastrointestinal 
tract  [25].  Neuroendocrine  cell  expression in  large  intestinal  adenocarcinomas 
was  found  to  be  more  when  compared  with  adenocarcinomas  at  other 
gastrointestinal sites (stomach) and extraintestinal sites like prostate and breast. 
The number of hormone products was also more in gastrointestinal tumors with 
neuroendocrine differentiation,  upto five different hormone products  have been 
noted in these tumors [26]. neuroendocrine cells were observed at the metastatic 
sites  of  these tumors.  Chromogranin A was the most reliable marker  to detect 
neuroendocrine expression in adenocarcinomas [25]
No exact correlation was found between the carcinoma differentiation and 
neuroendocrine  cell  expression.  Adenocarcinomas  with  neuroendocrine 
differentiation  showed  better  prognosis  than  those  without  neuroendocrine 
differentiation [26, 27].however in a study by Ooi et al endocrine differentiated 
tumor cells was seen to occur more frequently in gastric carcinomas of advanced 
stage [25].
IMMUNOHISTOCHEMISTRY
Immunohistochemistry  involves  two  disciplines  –  immunology  and 
histology.
Immunohistochemistry is used to not only to determine if a tissue expresses a 
particular antigen [or does not express] a particular antigen, but also determine the 
antigenic  status  of  particular  cells  within  that  tissue  and  the  micro  anatomic 
location of the antigen.
 Immunohistochemistry  uses  antibodies  to  distinguish  the  antigenic 
differences between cells.
These  differences  can  specifically  identify  the  lineage  of  cell  population, 
define biologically distinct populations of cells within the same lineage, identify 
functional differences between cells and can be used to identify specific infections. 
[28]
IHC  started  in  1940  when  Coons  developed  an  immunofluorescence 
technique to detect corresponding antigens in frozen sections [29].
IHC found wide application only since 1990 following series of technical 
developments such as enzyme label methods (horse radish peroxidase) developed 
by Avrameas and colleagues [30] 
The sensitivity of the technique increased when simple one step procedure 
was  converted  to  multistep  detection  procedure  such  as  Peroxidase-
Antiperoxidase, avidin-biotin conjugate and biotin streptavidin methods, together 
with amplification methods and highly sensitive polymer based labeling systems. 
[31]
Hybridoma technique facilitated the development of IHC and manufacture of 
abundant,  highly  specific  antibodies  many of  which found early  application in 
staining  of  tissues.  Brown  revolution  happened  when  IHC  was  applicable  to 
paraffin embedded tissue sections.
Taylor  and  colleagues  in  1974  showed  it  was  possible  to  demonstrate 
antigens in routinely processed tissue [32]
Huang  and  colleagues  introduced  enzyme  digestion  as  a  pre-treatment 
process to unmask antigens in formalin fixed tissues [33]
Leong and colleagues showed that enzyme digestion did not improve IHC 
staining [34]; the optimal digestion conditions were different for each antibody 
and difficult control.
Antigen retrieval technique is a simple method that involves heating paraffin 
processed sections at high temperatures before IHC staining. The technique was 
introduced  by  Shi  and  associates  in  1991[35].  Antigen  retrieval  technique 
improved  Immunohistochemical  staining  which  was  shown  by  numerous 
published articles [36].
PRINCIPLES OF IHC
The basic principle of IHC is a sharp localization of target 
components in the cell and tissue based on satisfactory signal to 
noise ratio. Amplifying the signal and reducing the non-specific 
background  staining  (noise)  achieves  a  practical  and  useful 
result.
IHC technique is a valuable adjunct that expands the variety 
of tissue components that can be demonstrated.
Antigen  –is  a  protein,  carbohydrate  or  lipid  molecule  which  bears  on  its 
surface one or more antibody-binding sites. These are highly specific topographic 
regions composed of small number of amino acids or monosaccharide units and 
are known as antigenic determinant groups or epitopes [37].
Antibodies – belong to a class of serum proteins known as immunoglobulins. 
Antibody molecule has the property of combining specifically  with the second 
molecule, termed as antigen.
Antigen-antibody  binding  –  the  amino  acid  side  chains  of  the  variable 
domain  of  an  antibody  form  a  cavity  which  is  geometrically  and  chemically 
complementary to a single type of antigen epitope.
The analogy of  lock (antibody) and key (antigen)  has  been used and the 
precise fit explains the high degree of antibody-antigen specificity seen. 
The associated antibody-antigen complex is held together by a combination 
of hydrogen bonds, electrostatic forces and van der Waal’s forces.
The use of an antibody in IHC depends on the sensitivity and specificity of 
the antigen-antibody reaction. The Hybridoma technique provides limitless source 
of highly specific antibodies.
Monoclonal  antibodies  cannot  guarantee  antigen  specificity  as  different 
antigens share similar reactive epitopes but practical specificity is high.
Polyclonal antibodies – an antiserum which contains several antibodies with 
different affinities and specificities. It carries the disadvantage of producing more 
non-specific background staining than monoclonal antibodies, but detects antigens 
which cannot be detected by monoclonal antibodies.
Polyclonal antibodies are more sensitive but less specific than monoclonal 
antibodies, as polyclonal antibodies may recognize several different epitopes on a 
single antigen whereas a monoclonal antibody recognizes only a single epitope. 
AR techniques with amplification systems have minimized this difference.
The specificity of the reaction can be assessed depending on the pattern of 
staining in control tissue sections. Correlation of the staining result with literature 
references for antigen distribution and comparing the staining of the test antibody 
with a second antibody known to bind to bind to the same antigen but different 
antibody [38].
Blocking non-specific background staining
Background  staining  is  due  to  either  non-specific  antibody  binding  or 
presence of endogenous enzymes. 
Non-specific  binding seen with polyclonal primary antibody is  minimized 
with pre-incubating sections with serum from same species on optimal working 
dilution. 
Endogenous  enzymes  such  as  peroxidase  seen  in  normal  and  neoplastic 
tissues abolished by peroxidase blocking or by using alternate systems such as 
immunogold or glucose technique. 
Methods suggested to overcome endogenous activity include incubation in 
methanol containing 0.5% hydrogen peroxide for 10 minutes at room temperature 
(almost  complete  abolition  of  endogenous  peroxidase  activity)[39],  alkaline 
phosphatase blocked with 1mM concentration of levamisole in the final incubation 
medium.  Enzyme  labels  glucose-oxidase  and  bacterial  beta-2-galactosidase  are 
non problematic.
Detection systems
Antibodies are labeled or flagged by some method to permit visualization; 
these  include  fluorescent  substances,  enzymes  forming  colored  reaction  with 
suitable  substrate  (Light  microscopy)  or  heavy  metals  (Electron  microscopy). 
These systems also enhance sensitivity through  signal amplification .
Different methods of IHC
DIRECT METHOD
• Direct conjugate-labeled antibody method
Antibody  is  attached  with  a  label  by  chemical  means  and  then  directly 
applied to tissue sections. It is a rapid and easy procedure, and is more useful with 
primary monoclonal antibodies. 
Disadvantages being difficulty in preparing final labeled reagent without free 
label molecules, detection of multiple antigens require separate incubation with the 
respective antibodies and high concentration of antibodies.
INDIRECT METHOD
• Indirect or sandwich procedure
Primary antibody that has specificity against desired antigen added, labeled 
secondary antibody which has specificity against an antigenic determinant is then 
added; it serves to localize the primary antibody and hence the site of antigen. This 
is the technique employed in this study. 
The  advantages  include  increased  versatility,  conjugation  applied  to 
secondary  antibody,  higher  working  dilution  of  primary  antibody,  secondary 
antibodies against primary antibodies of a different species easy to prepare and 
omission of primary antibodies during the process can act as a negative control.
• Unlabeled antibody methods
The original immune enzyme bridge method using enzyme specific antibody 
became rapidly superseded by the improved technique using a soluble peroxidase 
–  antiperoxidase  complex  (PAP).  Sternberger  and  colleagues  introduced  this 
technique for detecting treponemal antibodies [40]. These complexes are formed 
from 3 peroxidase molecules and 2 antiperoxidase antibody molecules and are 
used as a third layer in the staining method. They are added to the unconjugated 
primary  antibody  e.g.  rabbit  anti-human  IgG  by  a  second  layer  of  bridging 
antibody that is usually swine antirabbit applied in excess so that one of its two 
identical  binding  sites  binds  to  primary  antibody  and  the  other  to  rabbit  PAP 
complex. 
Alkaline phosphatase antibodies raised in mouse by the same principle can be 
used  to  form  the  alkaline  phosphatase-antialkline  phosphatase  complexes 
(APAAP).  For  unknown reasons  this  form of  amplification  APAAP is  not  as 
successful  as  the  PAP  technique  which  may  be  ascribed  to  the  excessive 
background staining 
• New indirect technique:
(Dextran polymer conjugate two step visualization system)
The primary antibody in enhanced polymer one step method is replaced with 
a secondary antibody. Available in either as anti-rabbit or an anti-mouse format it 
offers  greater  sensitivity  than  the  traditional  indirect  systems,  is  less  time 
consuming  than  the  3  stage  Avidin-biotin  system  and  does  not  react  with 
endogenous biotin.
• Avidin-biotin techniques
This  procedure  uses  the  high affinity  binding between biotin  and Avidin. 
Biotin is chemically linked to primary antibody and Avidin chemically conjugated 
to  enzyme.  The  Avidin  binds  to  biotinylated  antibody  thus  localizing  the 
peroxidase moiety at the site of antigen. 
Disadvantages include different affinities of different batches of biotin and 
Avidin, endogenous biotin producing non-specific background staining.
Avidin biotin conjugate procedure 
A modification of Avidin biotin method where the primary antibody is added 
followed by a biotinylated secondary antibody and next by preformed complexes 
of Avidin and biotin horse radish peroxidase conjugate . This is a more sensitive 
method [41].
• Biotin streptavidin systems 
Streptavidin is used in place of Avidin. This is more sensitive than Avidin 
biotin conjugate procedure and streptavidin enzyme complexes are more stable so 
they can be prepared well ahead.
• Hapten labeling techniques
Bridging techniques using haptens such as dinitrophenol and arsenilic acid have been 
advocated [42]. The Hapten is linked to primary antibody and a complex is built up using an 
anti-hapten antibody and either Hapten-labeled enzyme or Hapten labeled PAP complex.
• Immuno gold silver staining technique
This is used in ultrastructural immunolocalisation. The advantages were highlighted by 
Holgate et al in 1983 [43]. Gold particles are enhanced by addition of several layers of metallic 
silver. The low forming metallic silver has tolerance for natural light. This is more sensitive 
than the PAP technique but fine silver deposits in the background create confusion when small 
amounts of antigen are identified.
Tissue fixation, processing and antigen retrieval techniques:
Tissues for IHC undergo fixation, dehydration and paraffin embedding
Fixation 
This  is  a  critical  step  as  the  morphological  preservation  is  essential  for  IHC 
interpretation.  10%  buffered  neutral  formalin  commonly  used  because  of  the 
following advantages: 
1 Good morphological preservation 
2. Cheap 
3. Sterilizes tissues 
4. Carbohydrate antigens are better preserved [44] 
5. Many antigens are preserved during the process of cross linking. 
The disadvantage of masking of antigens during fixation can be overcome by 
antigen retrieval technique. Coagulant fixatives (ethanol) can also be used and are 
known to produce lesser changes in IHC changes. 
Subsequent  treatment  with  absolute  ethanol  during  dehydration  serves  as 
double fixation.
Antigen retrieval (AR)
Process involves unmasking of antigens by one of these four techniques: 
1. proteolytic enzyme digestion 
2. microwave antigen retrieval 
3. microwave and trypsin antigen retrieval technique 
4. pressure cooker antigen retrieval. 
Enzyme digestion is difficult to control and produces inconsistent results. In 
the  AR technique involving heat,  the result  is  influenced by heating condition 
(temperature and time of heating) and pH of the AR solution. High temperature 
being  the  most  important  factor.  Most  antigens  show  no  significant  variation 
between pH 1.0 to 10. AR technique enhances immunostaining and standardizes 
routine IHC [35].
 
Microwave AR technique is a new technique. Heating is done in plastic 
coplin  jars.  Drying  of  sections  can  take  place  and  hence  careful  monitoring 
required. Pressure cookers do not require close inspection and do not suffer from 
inconsistent results. In any of the conditions wherein heat is employed slides are 
coated with silane to prevent loss of sections.
MATERIALS AND METHODS
Source of data
A  total  of  152  resected  gastrointestinal  specimens  were  received  in  the 
department  of  pathology,  Stanley  Medical  College  from  general  surgical  and 
surgical  gastroenterology  departments  during  the  period  August  2005  to 
September 2007. Among these 26 specimens satisfied the criteria for the study.
Inclusion criteria
Tumors  which  on  histopathological  examination  showed  focal  or  diffuse 
neuroendocrine pattern.
Criteria for neuroendocrine differentiation
1. Architectural clues :
i. organoid  architecture  manifested  by  solid  nests,  sheets  and  broad 
trabeculae with peripheral pallisading
ii. Rosette  formation  which  is  common  to  neuroendocrine  tumors  of 
various organs
2. Cytological clues
i. Nuclear  features  –  fine  to  coarsely  granular  chromatin,  evenly 
distributed smooth nuclear membrane
ii.  Cytoplasmic features – uniform, polygonal and cuboidal cell shapes, 
slightly eosinophilic and finely granular cytoplasm, indistinct cytoplasm 
membrane, and ill defined cellular boundaries [45]
Exclusion criteria
Tumors with no evidence of neuroendocrine pattern.
Method of data collection
The  material  consisted  of  26  resected  gastrointestinal  specimens  which 
included 
2 gastrectomy specimens,
2 duodenojejunal resections
2 ileal resections
9 Whipple’s procedure specimens,
5 Right hemicolectomy specimens and
6 Abdominoperineal resection specimens. 
Method of  Tissue Preparation For IHC
10% buffered formalin has been used for fixation of specimens, the tissues 
were  processed  in  various  grades  of  alcohol  and  xylol.  Paraffin  blocks  were 
prepared and stained with hematoxylin and eosin. Suitable sections were chosen 
for IHC. 
Slides coated with chrome alum were used[49]. Sections subjected to AR 
using the microwave technique with citrate buffer solution. Slides then treated by 
HRP polymer technique.
Steps involved in the HRP polymer technique
1. Treatment with peroxidase block – for inhibiting endogenous peroxidases 
in the tissue for 20 minutes. Wash in TRIS buffer for 5 minutes.
2. Application  of  power  block  –  to  block  non-specific  antigen  antibody 
reactions for 20 minutes. The excess of power block is blot dried.
3. Application  of  primary  antibody  –  murine  antibodies  for  60  minutes. 
Wash in TRIS buffer for 5 minutes.
4. Application  of  super  enhancer  for  30  minutes  which  increases  the 
sensitivity  of  antigen  antibody  reaction  thereby  enhancing  the  final 
reaction product.
5. Application of SS label – secondary antibody from goat with the tagged 
horse radish peroxidase enzyme for 30 minutes. Wash in TRIS buffer.
6. Application  of  DAB  (diaminobenzidine)  chromogen  for  5  minutes  – 
which is cleaved by the enzyme to give the coloured product at antigen 
sites. Wash in distilled water for 5 minutes.
7. The slides are counterstained with hematoxylin. Slides are air dried and 
mounted with DPX.
The above polymer technique is found to be superior than the Avidin biotin 
system as it is more sensitive and can be used for a variety of primary antibodies 
(murine and rabbit).
Neuroendocrine  markers  used –  chromogranin  A  and  synaptophysin. 
Sections  negative  for  neuroendocrine  markers  were  treated  for  cytokeratin, 
lymphoma markers  (CD 45,  CD20,  CD 3),  HMB-45,  c-KIT depending on the 
tissue morphology of the sections.
Grading  of  immunohistochemical  neuroendocrine  marker  distribution 
[TRAVIS] [19].
• 0 – none
• 1 – < 10% of tumor cells
• 2 - 10% to 50% of tumor cells
• 3 - > 50% of tumor cells
Staining intensity
• 1+   = mild
• 2+   = moderate
• 3+   = marked
Criteria for neuroendocrine tumor-Neuroendocrine tumors were more than 
50% positive for neuroendocrine markers with a 2+ or 3+ staining intensity.
OBSERVATION AND RESULTS
 Based on the pattern and extent of neuroendocrine differentiation the 26 
tumors were grouped under 4 categories
1. Category A - tumors with predominantly neuroendocrine pattern. These cases 
showed rare  mitoses,  with no necrosis   –  HPE diagnosis  –  neuroendocrine 
tumors
2.  Category B - tumors with predominantly glandular pattern with focal areas of 
neuroendocrine pattern. Variable mitosis, foci of necrosis was observed  – HPE 
diagnosis adenocarcinoma with endocrine differentiation
3. Category C – tumors with predominantly solid sheets of cells with focal areas 
of neuroendocrine pattern. Numerous mitoses, large areas of necrosis noted – 
HPE  diagnosis  poorly  differentiated  carcinomas 
[adenocarcinomas/neuroendocrine carcinomas]
4. Category D – tumors with small round cells or spindle cells or with focal areas 
of neuroendocrine pattern. Variable mitosis, foci of necrosis was observed – 
HPE  diagnosis  small  cell  carcinomas,  lymphomas,  GIST  and  signet  ring 
carcinomas
Table no:1 – case distribution among the 4 categories
Site distribution
Of  the  26  resected  specimens  taken  for  study  majority  belong  to  the 
periampullary  region  (9  cases)  followed  by  rectum (6cases),  caecum (4 
cases),  the  stomach  (2  cases),  duodenum (2  cases),  ileum (2cases)  and 
ascending colon (1case).
Table no:2
Site distribution of cases
Site Frequency Percentage
Ascending colon 1 3.8
Caecum 4 15.4
Duodenum 2 7.7
Ileum 2 7.7
Periampullary region 9 34.6
Rectum 6 23.1
Stomach 2 7.7
Total 26 100.0
Age distribution
 The age distribution of the cases studied showed a range varying from 18 
-68yrs.
The majority  of  patients  were  in  the  40  -  49  yrs  age  group  (12  cases) 
followed by 50 – 59 yrs age group ( 6cases),  60 – 69 yrs age group (5 
cases). The age groups 10 – 19 yrs, 20 – 29 yrs and 30 – 39 yrs had one 
case each.
Table no:3
Age distribution of cases
Age group No. of cases Percentage
10 – 19 1 4
20 – 29 1 4
30 – 39 1 4
40 – 49 12 46
50 – 59 6 23
60 – 69 5 19
Statistical analysis of inter-category variations
Table no:4
Statistical analysis of age distribution
No. of cases 26
Mean 47.73
Std. Deviation 10.891
Minimum 18
Maximum 68
Table no:5
Percentage distribution of cases based on age
Age category No. of patients Percentage
<40 5 19.2
41-50 12 46.2
>50 9 34.6
Total 26 100.0
The mean age of occurrence was 47 years. When the total number of patients was 
subdivided into 3 groups as <40, 41-50, >50 the majority of the cases belonged to 
the 41-50 group (46.2%).
Sex distribution
Of the cases 15 were male and 11 were female patients. No statistical significance 
was found between tumor occurrence and sex distribution.
Table no:6
Sex distribution of cases
sex
 Male Female
 n % n %
Chi-square 
test
age <40 4 80.0% 1 20.0%
 41-50 5 41.7% 7 58.3%
 >50 6 66.7% 3 33.3%
Group Total 15 57.7% 11 42.3%
χ2=2.57
P=0.58
Not significant
Table no:7
Percentage distribution of cases amongst the categories
Category A
8 cases were included in this category.
Site of occurrence - 4 in periampullary region, 1 duodenum, 2 caecum, 1 
rectum.
Age – ranged from 18 years to 47 years.
Sex distribution – 5 were males and 3 females.
Histopathological  diagnosis  –  all  the  8  cases  were  diagnosed  as  well 
differentiated neuroendocrine tumors
Muscle  invasion  –  was  observed  in  1  case  alone,  all  the  others  were 
confined to the sub mucosal region.
Lymphnode  or  distant  spread-none  showed  evidence  of  lymphnode  or 
distant organ involvement
Immunohistochemistry  –  all  the  cases  were  >50%  positive  for 
Neuroendocrine markers with +3 intensity.
Follow-up – all the 8 cases were available for follow-up from 6 months to 
24 months. These patients were alive during this period.
Table no:8
Category A – neuroendocrine expression and extent of spread
Serial 
no.
Biopsy no. Neuroendocrine marker
% of 
positivity
Intensity of 
positivity
Muscle 
invasion
Lymphnode 
and distant 
spread
1 1012/05 >50% +3 _ _
2 3384/05 >50% +3 _ _
3 336/06 >50% +3 _ _
4 1129/06 >50% +3 _ _
5 3830/06 >50% +3 _ _
6 4238/06 >50% +3 _ _
7 1420/07 >50% +3 _ _
8 2655/07 >50% +3 + _
CATEGORY B 
7 cases were included in this category.
Site-  4  from  rectum  1  each  from  caecum,  ascending  colon  and 
periampullary region. 
Age-ranged from 44years to 68 years.
Sex- 3 were males and 4 were female patients.  
Histopathological  diagnosis-adenocarcinoma  with  neuroendocrine 
carcinoma.
Muscle  invasion-  muscle  invasion  was  observed  in  4  cases,  of  these 
Lymphnode  involvement  was  seen  in  2  cases  and  one  showed  liver 
metastasis. 
Table no:9
Category B-extent of neuroendocrine positivity
Serial no Biopsy no. Neuroendocrine marker 
- % of positive cells
Intensity of 
positivity
1 506/07 1-10% 2+
2 609/07 1-10% 2+
3 802/07 10-50% 3+
4 813/07 1-10% 2+
5 881/07 10-50% 2+
6 1627/07 10-50% 2+
7 2013/07 10-50% 2+
3 cases showed 1-10% positive cells with an intensity of  +3. the remainder 4 cases 
were positive for 10-50% cells with 3 of them belonging to +2 intensity and 1 case 
with +3 intensity.
Table no:10
Category B-expression of neuroendocrine expression and extent of tumor spread
All the 8 cases were alive during the period of follow up. 3 cases with 1-10% positivity 
and intensity of +2  were positive for muscle invasion and lymphnode involvement and 
1 showed liver metastases.
Of the 5 cases which showed 10-50% positivity and +2 to  +3 intensity, only one 
presented with muscle invasion none of them involved the lymphnodes or distant 
organs.
CATEGORY C
5 cases were included in this category
Sex- 3 were males and 2 females
 Age- ranged from 38 years to 54 years.
 Tumor Site - 4 cases were from periampullary region and 1 from stomach. 
All the 5 cases showed muscle and lymphnode involvement with one showing liver 
metastases.
IHC -All he 5 cases were treated with neuroendocrine markers (chromogranin A and 
synaptophysin) and cytokeratin.
Table no:11
Category C-neuroendocrine and cytokeratin expression
Serial 
no Biopsy no
Neuroendocrine markers
% of 
positivity
Intensity of 
positivity
Cytokeratin
1 3842/05 1-10% 2+ +
2 1121/05 >50% 3+  +
3 2486/05 1-10% 2+ +
4 4222/06 0 - +
5 2275/07 1-10% 2+ +
Follow-up 
Period of follow-up ranged from 6months to 18 months.2 patients died at 12 months, 1 
at 18 months, the remaining 2 were alive for a period of 18 and 6 months respectively.
Table no:12
Category C-extent of neuroendocrine expression and survival
S.no Biopsy no
Neuroendocrine 
marker
% of 
positivity
Intensity 
of 
positivity
Period of 
follow-up outcome
1 3842/05 1-10% 2+ 12 m Died
2 1121/06 >50% 3+ 12 m Died
3 2486/06 1-10% 2+ 18 m Died
4 4222/06 0 _ 18 m Alive
5 2275/06 1-10% 2+ 6 m Alive
CATEGORY D
6 cases were included in this category
 Age- ranged from 24years to 60 years
 Tumor site- 2 cases from ileum, 1 each from stomach, caecum and rectum.
Histopathological diagnosis
• 4 cases showed solid sheet like pattern with focal neuroendocrine 
arrangement and consisted of round to polygonal cells – DD 
lymphoma/neuroendocrine carcinoma/poorly differentiated carcinoma
• 2 cases showed sheet and focal neuroendocrine pattern composed of 
spindle shaped to round cells – DD 
GIST/neuroendocrinecarcinoma/malignant melanoma poorly 
differentiated carcinoma
Muscle invasion – noted in the 2 cases.
Lymphnode involvement – 3 cases showed lymphnode involvement.
IHC – in addition to neuroendocrine markers cytokeratin, c-kit, lymphoma markers 
and HMB-45 were applied.
Table no:13
Category D-IHC marker expression
S..no Biopsy no.
Neuroendocrine 
markers Cytokeratin c-kit
HMB-
45
Lymphoma 
markers
CD
20 CD45
Diagnosis
1 210/07 _ _ NA NA + + lymphoma
2 777/07 _ _ _ + NA NA Amelanotic 
melanoma
3 2219/07 _ _ NA NA + + lymphoma
4 2241/07 _ _ + _ NA NA GIST
5 2402/07 _ _ NA NA + + lymphoma
6 2517/07 _ + _ _ _ _ Poorly 
differentiated 
carcinoma
2 cases which showed mucle involvement were GIST and poorly differentiated 
carcinoma.
Lymphnode  involvement  which  was  observed  in  3  cases  included  2  cases  of 
lymphomas and 1 case of poorly differentiated carcinoma.
Follow up-cases were followed up from a minimum of 6 months all the patients 
were alive during this period.
STATISTICAL ANALYSIS AMONG THE 4 CATEGORIES 
Table no:14
Analysis of extent of neuroendocrine marker positivity in the 4 categories
Neuroendocrine 
marker
 
Category
A B C D
n % n % n % n %
Chi-square 
test
positivity 0 0 0% 0 0% 1 14.3% 6 85.7%
χ2=48.94
P=0.001
significant
 1-10
% 0 0% 3 50.0% 3 50.0% 0 0% 
 10-50
% 0 0% 4 100.0%  0% 0 0% 
 >50% 8 88.9% 0 0% 1 11.1% 0 0% 
Group Total 8 30.8% 7 26.9% 5 19.2% 6 23.1%
Table no:15
Extent Of Neuroendocrine Positivity Of The 26 Cases 
Neuroendocrine 
marker positivity
No Of 
cases
Diagnosis
0 7
Lymphoma – 3
Poorly differentiated adenocarcinoma – 2
Amelanotic melanoma – 1
GIST – 1
1-10% 6 Adenocarcinoma with neuroendocrine differentiation – 4
10-50% 4
Poorly differentiated adenocarcinoma – 3
Adenocarcinoma with neuroendocrine 
differentiation – 3
>50% 9
Well differentiated Neuroendocrine tumors – 
8
Large cell Neuroendocrine carcinoma – 1
Table no:16
Intensity of neuroendocrine marker positivity of the cases 
 
 
intensity
2 3
n % n % Chi-square test
positivity
 
 
1-10% 6 100.0%   
10-50% 3 75.0% 1 25.0%
>50%   9 100.0%
Group Total 9 47.4% 10 52.6%
χ2=15.99
P=0.001
significant
Extent of neuroendocrine positivity:
>50% positivity was seen in 9 of the 26 cases which includes 8 cases from 
category A and 1 from category B (8 cases of well differentiated neuroendocrine 
neoplasms and 1 case of large cell neuroendocrine carcinoma).
Intensity of neuroendocrine positivity:
19 cases were positive for neuroendocrine markers. Of these 19 cases, 9 
showed +2 intensity and 10 were of +3 intensity. These 9 cases showed <50% 
staining (6 with 1-10% and 3 with 10-50% positivity) and of the remaining 10,  9 
were >50% positive with 1 case being 10-50% positive. A significant association 
was found between the extent of staining and intensity of staining.
Frequency of positivity of other markers
Table no:17
Lymphoma Markers-frequency of positivity
Lymphoma 
markers
Frequency Percentage
_ 2 7.7
+ 3 11.5
NA 21 80.8
Total 26 100.0
Table no:18
C- Kit-frequency of positivity
c-kit Frequency Percentage
_ 2 7.7
+ 1 3.8
NA 23 88.5
Total 26 100.0
Table no:19
Cytokeratin – frequency of positivity
 Cytokeratin Frequency Percentage
No 13 50.0
Yes 13 50.0
Total 26 100.0
Table no:20
HMB -45-frequencyof positivity
 HMB-45 Frequency Percentage
- 2 7.7
+ 1 3.8
NA 23 88.5
Total 26 100.0
Muscle invasion in the 4 different categories
The Overall  frequency of  muscle  invasion  was 42.3% (11 cases).  Category  D 
showed muscle involvement in all the 5 cases (100%).
Table no:21
Frequency of muscle invasion 
Muscle 
invasion
Frequency Percentag
e
no 15 57.7%
yes 11 42.3%
Total 26 100.0
Table no:22
Frequency of muscle invasion in the 4 categories
Category
 
Muscle Invasion
no yes
n % n %
A 7 87.5% 1 12.5%
B 3 42.9% 4 57.1%
C 5 100.0%
D 4 83.3% 2 16.7%
Total 15 57.7% 11 42.3%
Lymphnode involvement in the 4 categories
The overall lymphnode positivity was 34.6% (9 cases). Category D showed 100% 
positivity with all the case showing lymphnode involvement.
Table no:23
Frequency of lymphnode involvement
Lymphnode 
involvement
Frequency Percentage
no 17 65.4
yes 9 34.6
Total 26 100.0
Table no:24
Frequency of lymphnode involvement in the  4 categories
Category
Lymph node positivity
no yes
n % n %
A 8 100.0%  
B 4 57.1% 3 42.9%
C  5 100.0%
D 3 50.0% 3 50.0%
 Total 15 57.6% 11 42.3%
Distant metastasis in the 4 categories
Distant metastasis was seen in 2 cases (1case from category B and 1 from category 
D).
Table no:25
Frequency of distant metastasis
 Distant 
metastasis
Frequency Percentage
no 25 92.4
yes 2 7.6
Total 26 100.0
Table no:26
Frequency of distant metastasis in the 4 categories
Category
 
Distant metastasis
no yes
n % n %
A 8 100.0%  
B 6 85.8% 1 14.2%
C 4 80.0% 1 20.0%
D 6 100.0%  
 Total 25 96.2% 1 3.8%
The final diagnosis based on the various IHC positivity patterns
Table no:27
Final diagnosis of the 26 cases
Final diagnosis Frequency Percentage
Adenocarcinoma with 
neuroendocrine Differentiation 7 26.9
Amelanotic melanoma 1 3.8
GIST 1 3.8
Large cell Neuroendocrine 
Carcinoma 1 3.8
Lymphoma 3 11.5
Neuroendocrine tumor 8 30.8
Poorly Differentiated 
adenocarcinoma 5 19.2
Total 26 100.0
Prognosis 
Category C showed a fall in the survival rate after 12 and 18 months. The other 
categories had a similar survival rate (all the patients survived during the period of 
follow up with no deaths) 
Kaplan Meier curve for comparison of survival of patients
Table no:28
Frequency of survival in the 4 categories
Category
 
 
status
Alive Died
n % n %
 Chi-square test
 
A 8 100.0%   
B 7 100.0%   
C 2 40.0% 3 60.0%
D 6 100.0%   
Total 23 88.5% 3 11.5%
χ2=14.23
P=0.003
significant
Category D showed the highest percentage of deaths 60% accounting for 3 cases.
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Neuroendocrine  differentiation  can  be  seen  in  a  wide  range  of 
gastrointestinal  neoplasms  which  greatly  differ  amongst  themselves  both  in 
morphological and behavioral pattern. Although admixtures and overlaps occur, 
most of the gastrointestinal tumors with neuroendocrine differentiation have been 
placed into following categories – 
well differentiated neuroendocrine tumors
neuroendocrine tumors with atypical morphological features, 
small cell carcinomas 
adenocarcinomas with neuroendocrine cells
In the present study over a period of two years, 26 cases have been selected 
among  a  total  of  152  gastrointestinal  resected  specimens  which  on  routine 
histopathological  examination  with  hematoxylin  and  eosin  sections  showed 
variable degree of neuroendocrine differentiation.
The selected cases have been placed under 4 categories
1. Category A - tumors with predominantly neuroendocrine pattern. 
These  cases  showed  rare  mitoses,  with  no  necrosis  –  HPE 
diagnosis – neuroendocrine tumors
2. Category B - tumors with predominantly glandular pattern with focal 
areas of neuroendocrine pattern.  Variable mitosis, foci of necrosis 
was  observed  –  HPE  diagnosis  adenocarcinoma  with  endocrine 
differentiation. 
2. Category C - tumors with predominantly solid sheets of cells with 
focal  areas of  neuroendocrine pattern.  Numerous mitoses,  large 
areas  of  necrosis  noted  –  HPE diagnosis  poorly  differentiated 
carcinomas  [poorly  differentiated   adenocarcinomas/ 
neuroendocrine carcinomas]. 
4. Category D - tumors with small round cells  or spindle cells with 
focal  areas  of  neuroendocrine  pattern.  Variable  mitosis,  foci  of 
necrosis  was  observed.   –  HPE diagnosis  small  cell  carcinomas, 
lymphomas, GIST and signet ring carcinomas.
Category A includes 8 cases.  All these 8 cases showed a predominantly 
neuroendocrine  pattern  (>  50%)  on  HPE.  Histological  diagnosis  of  well 
differentiated neuroendocrine tumors was given (carcinoids). Consistent with the 
criteria  proposed  by  Travis  all  the  8  cases  were  highly  (>  50%)  positive  for 
neuroendocrine markers with +3 intensity. The average age of occurrence in the 
present study is 40.5 years, with the youngest patient being 18 years old. 
Well  differentiated  neuroendocrine  tumors  are  reported  to  occur 
predominantly  in  adults  but  have  also  been  known  to  occur  in  children  [46]. 
Predominant site of occurrence was in the periampullary region.
 Previous  literature  cites  that  60%  of  these  well  differentiated 
neuroendocrine  tumors  occurring  within  the  gastrointestinal  tract  have  their 
location  in  the  appendix  followed  by  small  intestine,  rectum  and  stomach. 
However Yukata Noda et al  and Mark Hartel et al in separate studies concluded 
that periampullary carcinoids are more common than initially thought [24, 47]. All 
but 1 case were confined to the submucosa.
 The 8 patients survived for follow up period ranging from 6 months to 24 
months and showed no evidence of recurrence or metastasis. Well differentiated 
neuroendocrine  tumors  are  considered  to  be  indolent  tumors  and  the  5  year 
survival  rate  was  found to  be  more  than  90% [47].  This  study also  reflects  a 
similar observation within the period of study.  
Category B includes 7 cases. The neuroendocrine marker positivity ranged 
from 1-10% in 3 cases and 10-50% in 4 cases. The predominant tumor site in this 
group was rectum (4 cases) followed by 1 case in periampullary region, caecum 
and ascending colon. All these tumors were also positive for cytokeratin. Taking 
into  consideration  diffuse  positivity  for  cytokeratin  and  <  50%  positivity  for 
neuroendocrine markers these tumors were designated as adenocarcinomas with 
neuroendocrine  differentiation.  Among  adenocarcinomas  with  neuroendocrine 
cells, large intestinal adenocarcinomas come first [26]. In this study 6 out of the 7 
cases were from large intestine. These cases were followed up for a period of 6 to 
12 months. All the 7 cases survived during this period. However on comparing the 
degree of neuroendocrine positivity and extent of tumor spread it has been found 
that  in  4  cases  with  10%-50%  positivity  and  +2  to  +3  intensity  none  had 
lymphnode or distant organ involvement, on the other hand 3 cases with < 10% 
positivity and +2 intensity presented with advanced disease (all 3 with evidence of 
muscle invasion and lymphnode involvement and 1 with liver metastasis). Overall 
intensity of staining in adenocarcinomas is less than neuroendocrine tumors [19]. 
The  staining  intensity  in  this  category  consisting  of  adenocarcinomas  with 
neuroendocrine differentiation the intensity is +2 in 7 cases with +3 in 1 case only. 
Regarding  neuroendocrine  differentiation  in  gastrointestinal  adenocarcinomas 
conflicting  reports  have  been  published.  Akishi  Ooi  et  al  has  claimed  that 
increased  neuroendocrine  differentiation  in  adenocarcinomas  of  stomach  was 
associated with advanced disease [25]. Radi et al in gastric adenocarcinomas and 
Gen-You  et  al  in  large  intestinal  adenocarcinomas  had  showed  that 
neuroendocrine immunoreactivity was associated with less advanced disease and 
carry a good prognosis [26, 27]. Similar to the latter our study showed greater 
neuroendocrine immunoreactivity to be associated with limited disease.
Category C includes 5 cases. These were histologically classified as poorly 
differentiated carcinomas. Of these, 1 case which was from periampullary region 
showed > 50% positivity for neuroendocrine marker with grade 3 intensity. This 
tumor was therefore diagnosed as large cell neuroendocrine carcinoma. 
Large cell neuroendocrine carcinoma is a recently introduced entity in the 
gastrointestinal neuroendocrine neoplasms and has been reported in various sites 
with periampullary region being a rare site [47, 48]. The other 4 cases showed 0 to 
10%  immunoreactivity  for  neuroendocrine  markers  and  diffuse  positivity  for 
cytokeratin.  Based  on  the  criteria  recommended  by  Travis  these  tumors  were 
designated as poorly differentiated adenocarcinomas (with some neuroendocrine 
positive cells). 
The prognosis  of large cell  neuroendocrine carcinomas was found to be 
significantly worse than adenocarcinomas; this was observed by Sheryl R. Simon 
et al in their study of neuroendocrine carcinomas of the colon and Shi-Xu Jiang et 
al in their study of gastric large cell neuroendocrine carcinomas [22, 45]. These 
tumors  behave  aggressively  and  require  radical  surgery  and  chemotherapy  in 
comparison with well differentiated neuroendocrine tumors [45]. 
In accordance with the above reports,  this study shows that patient  with 
large  cell  neuroendocrine  carcinoma survived for  12  months  only.  Among the 
poorly differentiated adenocarcinomas 2 out of the 4 died, at 12 months and 18 
months respectively, this poor prognosis is similar to the earlier observations of 
decreased  survival  in  high  grade  carcinomas  with  or  without  neuroendocrine 
positivity and that it is not significantly different from large cell neuroendocrine 
carcinomas [45]. 
Category D consists of 6 cases. This category includes tumors which posed 
diagnostic difficulties due to a combination of varied morphological appearances. 
None  of  the  cases  were  positive  for  neuroendocrine  markers,  therefore 
neuroendocrine tumors or neuroendocrine differentiation was ruled out.  3 cases 
were for positive lymphoma markers,  1 case positive for c-kit,  1 case positive 
HMB-45,  1  case  for  cytokeratin,  hence  diagnosed  as  lymphoma,  GIST 
(Gastrointestinal  stromal  tumor),  amelanotic  melanoma  and  adenocarcinoma 
respectively. The follow-up period was 6 months and all of them survived during 
this time.
Neuroendocrine  markers  have  helped  confirm  neuroendocrine  nature  in 
category A, endocrine differentiation in otherwise exocrine tumors in category B, 
to  differentiate  large  cell  neuroendocrine  carcinoma  from  other  high  grade 
carcinomas in category C and rule out neuroendocrine carcinomas in tumors with 
varied morphological appearances in category D.
The prognostic implication varies among the 4 groups. Category A - well 
differentiated neuroendocrine tumors carries an excellent prognosis. Category B - 
adenocarcinomas  with  neuroendocrine  differentiation,  shows  less  advanced 
disease associated with more extensive neuroendocrine positivity. Category C –
large cell  neuroendocrine carcinoma and other poorly differentiated carcinomas 
associated with poorer prognosis. Category D- prognosis varies depending on the 
histological nature of these tumors. Among the 4 categories,  category C carries 
the  worst  prognosis.  However  the  available  period  of  review  has  not  been 
consistent in all the cases, varying from 6 months to 24 months, hence a longer 
period of follow-up in these cases will through more light on the behavior of these 
tumors. 
SUMMARY AND CONCLUSION
During the period of study between August 2005 and September 2007 the 
26  gastrointestinal  resected  specimens  with  evidence  of  neuroendocrine 
differentiation  were  taken  up  to  confirm  and  detect  neuroendocrine 
immunoreactivity.
Based  on  morphological  features  and   extent  of  neuroendocrine 
differentiation division of these 26 cases into 4 categories was done.
 IHC has helped confirm histological diagnosis of neuroendocrine tumors, to 
detect  neuroendocrine  expression  in  adenocarcinomas  and  make  a  definitive 
diagnosis in tumors with varied morphology. This is essential as the prognosis and 
treatment modalities vary amongst these tumours.
Poorly differentiated carcinomas and large cell neuroendocrine carcinoma 
were found to be associated with grim prognosis. In case of  adenocarcinomas 
with  neuroendocrine  differentiation,  tumours  with  greater  neuroendocrine 
reactivity  were  less  advanced  than  adenocarcinomas  with  minimal  or  no 
neuroendocrine reactivity. Since the period of follow-up is not uniform in all the 
cases and not more than 24 months,  a longer period of review is necessary to 
arrive at a definitive prognosis.
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